At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 831 enrolled
Drug / intervention
Ipilimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma
In Brief
A Phase 3 clinical trial evaluating Ipilimumab for Melanoma. Completed, enrolled 831 participants across 88 sites in 22 countries.
Detailed Summary
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesArgentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartFeb 2012
Primary CompletionFeb 2016
Study CompletionAug 2017
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartFeb 17, 2012
Primary CompletionFeb 6, 2016
Study CompletionAug 17, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 14.4 years ago
Interventions
Ipilimumabbiological